Medexus Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Medexus Pharmaceuticals has been growing earnings at an average annual rate of 17.5%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 24.6% per year. Medexus Pharmaceuticals's return on equity is 19.9%, and it has net margins of 5.1%.
Key information
17.5%
Earnings growth rate
23.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 24.6% |
| Return on equity | 19.9% |
| Net Margin | 5.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
Mar 03
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Jan 06Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Oct 11Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 11Medexus Pharmaceuticals (TSE:MDP) Use Of Debt Could Be Considered Risky
Jan 19Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Sep 22Is Medexus Pharmaceuticals (TSE:MDP) Weighed On By Its Debt Load?
Dec 16Medexus Pharmaceuticals Inc. (TSE:MDP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 21Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Aug 04Medexus Pharmaceuticals Inc. (CVE:MDP): When Will It Breakeven?
May 04The Independent Director of Medexus Pharmaceuticals Inc. (CVE:MDP), Michael Mueller, Just Bought 34% More Shares
Feb 26Did Business Growth Power Medexus Pharmaceuticals' (CVE:MDP) Share Price Gain of 174%?
Feb 24Revenue & Expenses BreakdownBeta
How Medexus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 116 | 6 | 46 | 2 |
| 30 Sep 23 | 119 | 5 | 47 | 3 |
| 30 Jun 23 | 117 | 3 | 48 | 3 |
| 31 Mar 23 | 108 | 1 | 48 | 3 |
| 31 Dec 22 | 100 | -11 | 47 | 3 |
| 30 Sep 22 | 92 | -11 | 46 | 3 |
| 30 Jun 22 | 82 | 2 | 44 | 4 |
| 31 Mar 22 | 77 | -3 | 44 | 6 |
| 31 Dec 21 | 74 | -8 | 44 | 7 |
| 30 Sep 21 | 77 | -20 | 43 | 7 |
| 30 Jun 21 | 77 | -31 | 40 | 6 |
| 31 Mar 21 | 80 | -28 | 36 | 5 |
| 31 Dec 20 | 79 | -19 | 33 | 3 |
| 30 Sep 20 | 69 | -9 | 31 | 2 |
| 30 Jun 20 | 64 | -7 | 31 | 2 |
| 31 Mar 20 | 56 | -5 | 31 | 1 |
| 31 Dec 19 | 47 | -4 | 31 | 1 |
| 30 Sep 19 | 45 | -3 | 29 | 0 |
| 30 Jun 19 | 36 | -6 | 22 | 0 |
| 31 Mar 19 | 25 | -5 | 16 | 0 |
| 31 Dec 18 | 17 | -5 | 10 | 0 |
| 30 Sep 18 | 9 | -5 | 6 | 0 |
| 30 Jun 18 | 8 | -2 | 6 | 0 |
| 31 Mar 18 | 8 | -3 | 6 | 0 |
| 31 Dec 17 | 8 | -3 | 6 | 0 |
| 30 Sep 17 | 7 | -3 | 6 | 0 |
| 30 Jun 17 | 6 | -3 | 6 | 0 |
| 31 Mar 17 | 5 | -1 | 5 | 0 |
| 31 Dec 16 | 4 | 1 | 5 | 0 |
| 30 Sep 16 | 3 | 1 | 5 | 0 |
| 30 Jun 16 | 3 | 1 | 5 | 0 |
| 31 Mar 16 | 3 | -2 | 5 | 0 |
| 31 Dec 15 | 3 | -4 | 5 | 0 |
| 30 Sep 15 | 2 | -4 | 5 | 0 |
| 30 Jun 15 | 2 | -5 | 6 | 0 |
| 31 Mar 15 | 2 | -4 | 6 | 0 |
| 31 Dec 14 | 3 | -4 | 6 | 0 |
| 30 Sep 14 | 3 | -4 | 5 | 0 |
| 30 Jun 14 | 4 | -3 | 5 | 0 |
| 31 Mar 14 | 3 | -3 | 5 | 0 |
| 31 Dec 13 | 4 | -2 | 4 | 0 |
| 30 Sep 13 | 3 | -1 | 4 | 0 |
| 30 Jun 13 | 3 | -2 | 4 | 0 |
Quality Earnings: MDP has high quality earnings.
Growing Profit Margin: MDP became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MDP has become profitable over the past 5 years, growing earnings by 17.5% per year.
Accelerating Growth: MDP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: MDP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: MDP's Return on Equity (19.9%) is considered low.